source
- Biotech sector expected to weather Fed rate hike despite higher capital costsThe Federal Reserve raised the federal funds rate by a quarter of a percentage point, a move that traditionally weighs on capital‑intensive industries like biotech. Analysts at BMO Capital Markets…
- Longeveron shares plunge 57% after stem-cell therapy fails in mid-stage heart trialLongeveron announced that its investigational stem cell product, laromestrocel, did not meet its primary endpoint in a Phase 2b study of infants with hypoplastic left heart syndrome (HLHS). The tri…